These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15571173)

  • 41. Shigella isolation in Vellore, south India (1997-2001).
    Jesudason MV
    Indian J Med Res; 2002 Jan; 115():11-3. PubMed ID: 12424931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nalidixic acid is still the drug of choice for shigellosis in Pakistan.
    Mahmood A
    J Pak Med Assoc; 2001 Feb; 51(2):101. PubMed ID: 11321869
    [No Abstract]   [Full Text] [Related]  

  • 43. Risk factors for death in hospitalized dysentery patients in Rwanda.
    Legros D; Paquet C; Dorlencourt F; Saoult E
    Trop Med Int Health; 1999 Jun; 4(6):428-32. PubMed ID: 10444318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro activity of tigecycline and other antimicrobial agents against Shigella species from Kuwait and the United Arab of Emirates.
    Jamal W; Rotimi VO; Pal T; Sonnevend A; Dimitrov TS
    J Infect Public Health; 2010; 3(1):35-42. PubMed ID: 20701889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nalidixic acid in Shigella dysenteriae outbreaks.
    Malengreau M
    Lancet; 1984 Jul; 2(8395):172. PubMed ID: 6146074
    [No Abstract]   [Full Text] [Related]  

  • 46. Nalidixic-acid-resistant Shigella dysenteriae I.
    Panhotra BR; Desai B; Sharma PL
    Lancet; 1985 Mar; 1(8431):763. PubMed ID: 2858035
    [No Abstract]   [Full Text] [Related]  

  • 47. Prevalence and susceptibility of Shigella species to 11 antibiotics in a Kuwait teaching hospital.
    Jamal WY; Rotimi VO; Chugh TD; Pal T
    J Chemother; 1998 Aug; 10(4):285-90. PubMed ID: 9720466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.
    Rogerie F; Ott D; Vandepitte J; Verbist L; Lemmens P; Habiyaremye I
    Antimicrob Agents Chemother; 1986 May; 29(5):883-6. PubMed ID: 3524434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changing patterns of drug-resistant Shigella isolates in egypt.
    Abd-Elmeged GM; Khairy RM; Abo-Eloyoon SM; Abdelwahab SF
    Microb Drug Resist; 2015 Jun; 21(3):286-91. PubMed ID: 25495749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nalidixic acid for shigellosis.
    McCormack JG
    Lancet; 1983 Nov; 2(8358):1091. PubMed ID: 6138641
    [No Abstract]   [Full Text] [Related]  

  • 51. Randomized clinical trial of norfloxacin for shigellosis.
    Bhattacharya SK; Bhattacharya MK; Dutta P; Sen D; Rasaily R; Moitra A; Pal SC
    Am J Trop Med Hyg; 1991 Dec; 45(6):683-7. PubMed ID: 1763794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency of isolation of shigella serogroups/serotypes and their antimicrobial susceptibility pattern in children from slum areas in Karachi.
    Zafar A; Sabir N; Bhutta ZA
    J Pak Med Assoc; 2005 May; 55(5):184-8. PubMed ID: 15960281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis.
    Salam MA; Bennish ML
    J Pediatr; 1988 Nov; 113(5):901-7. PubMed ID: 3054035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shigella isolates of Nepal: changes in the incidence of shigella subgroups and trends of antimicrobial susceptibility pattern.
    Kansakar P; Malla S; Ghimire GR
    Kathmandu Univ Med J (KUMJ); 2007; 5(1):32-7. PubMed ID: 18603983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transferable multiple drug resistance in enterobacteria from non-human primates. I. Development and characteristics of resistance in Shigella Flexneri.
    Hardy PH; Lindsey JR; Melby EC
    Johns Hopkins Med J; 1968 Jul; 123(1):29-37. PubMed ID: 5667656
    [No Abstract]   [Full Text] [Related]  

  • 56. Epidemic dysentery caused by Shigella dysenteriae type 1: a sentinel site surveillance of antimicrobial resistance patterns in Burundi.
    Engels D; Madaras T; Nyandwi S; Murray J
    Bull World Health Organ; 1995; 73(6):787-91. PubMed ID: 8907772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effectiveness of antibiotics in current treatment of dysentery].
    Bruckner S; Teodorescu G; Cotarcea S; Predescu I; Taindel C; Tesio C; Georgescu M; Burlacu G
    Pediatria (Bucur); 1971; 20(4):333-9. PubMed ID: 5096667
    [No Abstract]   [Full Text] [Related]  

  • 58. Increasing resistance to nalidixic acid in Shigella subgroups in a comparative study between 2001-2003 and 2004-2006.
    Mamishi S; Mashoori N; Mahboobi N; Pour Akbari B
    Singapore Med J; 2009 Aug; 50(8):791-3. PubMed ID: 19710978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2004-2011.
    Zhang J; Jin H; Hu J; Yuan Z; Shi W; Yang X; Xu X; Meng J
    Diagn Microbiol Infect Dis; 2014 Mar; 78(3):282-6. PubMed ID: 24387959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis.
    Salam MA; Dhar U; Khan WA; Bennish ML
    Lancet; 1998 Aug; 352(9127):522-7. PubMed ID: 9716056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.